Press release
Migraine Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AXS-07, STS-101, Zavegepant, TNX1900, Rimegepant
Migraine Pipeline
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Migraine pipeline constitutes 30+ key companies continuously working towards developing 30+ Migraine treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Migraine Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.
The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ [https://www.delveinsight.com/report-store/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key takeaways from the Migraine Pipeline Report:
* Migraine Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years.
* Migraine companies working in the treatment market are Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, Tonix Pharmaceuticals, BetterLife Pharma, and others, are developing therapies for the Migraine treatment
* Emerging Migraine therapies such as AXS-07, STS-101, Zavegepant, TNX1900 and others are expected to have a significant impact on the Migraine market in the coming years.
* On April 2024, AbbVie announced results of a Randomized, Double-Blind, Parallel-Group, and Active Controlled Trial with Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE).
* On April 2024, Pfizer announced results of a Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens.
* On November 2023, AbbVie announced results of a Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, and Parallel-Group Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine.
Migraine Overview
Migraine, a neurological disorder characterized by recurrent headaches, affects millions worldwide. These debilitating headaches are often accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound.
Understanding the complexity of migraines involves delving into various factors, including genetic predisposition, environmental triggers, and neurotransmitter imbalances. While the exact cause remains elusive, research suggests that changes in the brainstem and its interactions with the trigeminal nerve play a crucial role in migraine onset.
Managing migraines encompasses a multifaceted approach, ranging from lifestyle modifications to pharmacological interventions. From over-the-counter pain relievers to preventive medications, treatment strategies aim to alleviate symptoms and improve quality of life for migraine sufferers.
As awareness grows, so does the pursuit of innovative therapies. Ongoing research into novel drugs and neuromodulation techniques offers hope for more effective migraine management in the future.
Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment- [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Migraine Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Migraine Molecule Type
Migraine Products have been categorized under various Molecule types, such as
* Oligonucleotide
* Peptide
* Small molecule
Migraine Pipeline Therapeutics Assessment
* Migraine Assessment by Product Type
* Migraine By Stage and Product Type
* Migraine Assessment by Route of Administration
* Migraine By Stage and Route of Administration
* Migraine Assessment by Molecule Type
* Migraine by Stage and Molecule Type
DelveInsight's Migraine Report covers around 30+ products under different phases of clinical development like-
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies - [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Migraine Pipeline Analysis:
The Migraine pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
* Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.
Download Sample PDF Report to know more about Migraine drugs and therapies- [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of Migraine Pipeline Drug Insight
* Coverage: Global
* Key Migraine Companies: Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, Tonix Pharmaceuticals, BetterLife Pharma, and others.
* Key Migraine Therapies: AXS-07, STS-101, Zavegepant, TNX1900 and others.
* Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
* Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials- [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Migraine Report Introduction
2. Migraine Executive Summary
3. Migraine Overview
4. Migraine- Analytical Perspective In-depth Commercial Assessment
5. Migraine Pipeline Therapeutics
6. Migraine Late Stage Products (Phase II/III)
7. Migraine Mid Stage Products (Phase II)
8. Migraine Early Stage Products (Phase I)
9. Migraine Preclinical Stage Products
10. Migraine Therapeutics Assessment
11. Migraine Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Migraine Companies
14. Migraine Key Products
15. Migraine Unmet Needs
16 . Migraine Market Drivers and Barriers
17. Migraine Future Perspectives and Conclusion
18. Migraine Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=migraine-pipeline-assessment-2024-fda-ema-pdma-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-axs07-sts101-zavegepant-tnx1900-rimegepant]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AXS-07, STS-101, Zavegepant, TNX1900, Rimegepant here
News-ID: 3479764 • Views: …
More Releases from ABNewswire
The Bold Appeal of Skull Rings: Why the Head Ring is a Timeless Statement Piece
Jewelry has always carried meaning whether it's about faith, status, or personal identity. Among the most distinctive and bold choices is the skull ring [https://theswaf.com/collections/biker-skull-rings], a piece that has grown from subcultural symbolism into a mainstream fashion statement. Known for its edgy design and deep-rooted meanings, the head ring continues to attract bikers, rock enthusiasts, and fashion-forward individuals who want to make a lasting impression.
The History Behind Skull Rings
The…
ZamSafari Dome & Tale Green City: Zambia's 306-Acre Guinness World Record Mega-P …
Image: https://www.abnewswire.com/upload/2025/09/062c5a9ec8cd25b013fd631f8c93bd99.jpg
London, United Kingdom - 8th September, 2025 - Zambia is set to make history with the unveiling of the ZamSafari Dome & Tale Green City, a 306-acre mega-development in Chisamba that will feature Africa's first indoor safari dome and waterpark, luxury residential estates, international retail, and a fully integrated smart city.
What makes ZamSafari extraordinary is its ambition: the project is designed to achieve 17 Guinness World Record claimables, including…
Negola's Animal Care Announces Name Change to Columbia Animal Care
Local Veterinary Practice Strengthens Community Connection with New Name
Columbia, MD - Negola's Animal Care, a trusted veterinary practice [https://columbiaanimalcare.com/] serving the Columbia, Maryland community, today announced it will change its name to Columbia Animal Care, effective August 28, 2025. The practice will continue to operate under the same ownership and management, providing the same high-quality veterinary services that pet families have come to rely on.
Commitment to Excellence Remains Unchanged
"While our…
CE-LINK Unveils PD3.1 67W USB-C Dual Port Wall Charger with Built-in 1-Meter Ret …
Image: https://www.abnewswire.com/upload/2025/09/b1e0b3cbe35c3ad9851c333f33e00647.jpg
CE-LINK, a global leader in consumer electronics manufacturing, proudly unveils its latest innovation: PD3.1 67W USB-C Dual-Port Wall Charger with a built-in 1 meter(3.28 feet) retractable cable. Designed with cutting-edge GaN technology, exceptional durability, and user-friendly portability, this compact charger delivers a powerful, all-in-one fast-charging experience for today's connected lifestyle.
Dual GaN Fast Charging
Powered by a dual GaN chip design, this charger delivers up to 67W of PD3.1 fast charging…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
